Compare Moderna, Inc. (MRNA) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vital Farms Inc — how do they compare? Moderna, Inc. trades at $136.43 (market cap $56.02B), while Vital Farms Inc trades at $9.81 (market cap $432.32M). The key difference: Moderna, Inc. is far larger — about 129.6× Vital Farms Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | VITL | |
|---|---|---|
Market Cap | $56.02B | $432.32M |
Sector | Health | Consumer Staples |
52-Week High | $174.38 | $48.56 |
52-Week Low | $22.36 | $8.28 |
Enterprise Value | $52.17B | $519.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Vital Farms (VITL) trades at $10.08, up 1.61% on the day, but faces bearish technical signals with key support at $9. The company reported a challenging Q2 2026 with a net loss per share of $0.47, though revenue of $166 million slightly beat expectations. Gross margin collapsed to 6.6% amid industry oversupply, but management reaffirmed full-year guidance and secured a $125 million term loan for stability.
The outlook is cautious; analyst consensus is a Buy with a $13.00 price target, but near-term risks include persistent margin pressure, cash burn, and competitive pricing gaps. Long-term recovery depends on execution against guidance and market stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
